Home › Steatotic Liver Disease › NCT07495332

Siemens Biomarker Multi-modality

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age of 18 years or older
* Has clinically indicated CT schedule including the liver (with contrast or with and without contrast)
* Patient eligible for MR imaging
* History of chronic diffuse liver disease, steatotic liver disease, and/ or liver fibrosis
* Capable of consent

Exclusion Criteria:

* Contraindications to any of the required imaging examinations
* BMI \> 45 (based on MRI scanner capacity)

About the study

The purpose of this study is to see how well Photon Counting CT (PCCT) and ultrasound test results can find fat and scarring in the liver. They will be compared to MRI test results as the reference standard. Participants will get a regular CT scan on the PCCT scanner, plus a few extra pictures just for the study. They will also get an MRI, either on the same day or a different day, whichever is preferred. Participants will get an ultrasound on the same day as the MRI. If they have not had a hematocrit blood test in the past 24 hours, they will also receive one on the day of the CT scan.

What is being tested

• Photon-counting CT (PCCT) (diagnostic test)
• Ultrasound (diagnostic test)
• Magnetic Resonance Imaging (MRI) (diagnostic test)

Sponsor: Duke University · Participants: 45 · Started: Mar 27, 2026

Contact the study team

• Mustafa Bashir, MD · Phone: 919-684-7366

Official record on ClinicalTrials.gov — NCT07495332

Locations in the U.S.

Conditions

• Steatotic Liver Disease
• Cirrhosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.